Sale!

Buy Tofacinix 5 mg (Tofacitinib)

Original price was: $100.00.Current price is: $50.00.

Description

What is Tofacinix 5 mg (Tofacitinib)?

Tofacinix (Tofacitinib) is used alone or with other medications to treat rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) in adults who are unable to take or did not respond to one or more tumor necrosis factor (TNF) inhibitor medication(s). It is also used to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults who are unable to take or did not respond to or tolerate one or more TNF inhibitor medication(s).

Tofacitinib is used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s). It is also used to treat polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children 2 years and older who are unable to take or who did not respond to one or more TNF inhibitor medication(s). Tofacitinib is in a class of medications called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system. To know more about tofacitinib visit here.

Why should you buy the generic Tofacinix 5 mg online?

First of all generic Tofacinix is very affordable version of Tofacitinib for rheumatoid arthritis patients.  It is a verified generic version of  Xeljanz. Beacon pharmaceuticals Limited manufacture this generic version in Bangladesh. It is one of the renowned pharmaceutical companies who mostly made cancer medicine in Bangladesh. After the Directorate General of Drug Administration of Bangladesh approves to manufacture tofacitinib they started to make it and sell it all over the world where generic medicine is allowed to use.

It is the first generic version of Xeljanz which is selling regularly all over the world. It is also 95% cheaper than the brand version Which cost you less than 60 dollars. We also have apremilast and upadacitinib. both medicines use for arthritis treatment. You can visit our shop page to know about those medicines.

COMPOSITION

Tofacinix 5 Tablet: Each film coated tablet contains Tofacitinibcitrate equivalent to Tofacitinib 5 mg.
Tofacinix 11 Tablet: Each film coated tablet contains Tofacitinib citrate equivalent to Tofacitinib 11 mg.

Therapeutic Class

Antirheumatic drug.

PHARMACOLOGICAL ACTION OF TOFACINIX

Mechanism of Action

Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression.

Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. However, the relevance of specific JAK combinations to therapeutic effectiveness is not known.

Pharmacokinetics

Absorption

Tofacitinib 5 mg
The absolute oral bioavailability of Tofacitinib is 74%. Coadministration of Tofacitinib with a high-fat meal resulted in no changes in AUC while Cmax was reduced by 32%. In clinical trials, Tofacitinib was administered without regard to meals.

Tofacitinib XR 11 mg
Coadministration of Tofacitinib XR with a high-fat meal resulted in no changes in AUC while Cmax was increased by 27% and Tmax was extended by approximately 1 hour.

Distribution

After intravenous administration, the volume of distribution is 87 L. The protein binding of Tofacitinib is ~40%. Tofacitinib binds predominantly to albumin and does not appear to bind to α1-acid
glycoprotein. Tofacitinib distributes equally between red blood cells and plasma.

Metabolism and Elimination

Clearance mechanisms for Tofacitinib are approximately 70% hepatic metabolism and 30% renal excretion of the parent drug. The metabolism of Tofacitinib is primarily mediated by CYP3A4 with minor contribution from CYP2C19. In a human radiolabeled study, more than 65% of the total circulating radioactivity was accounted for by unchanged Tofacitinib, with the remaining 35% attributed to 8 metabolites, each accounting for less than 8% of total radioactivity. The pharmacologic activity of Tofacitinib is attributed to the parent molecule.

CLINICAL INFORMATION

Indication

Rheumatoid Arthritis

• Tofacitinib/Tofacitinib XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

• Limitations of Use: Use of Tofacitinib/Tofacitinib XR in combination with biologic DMARDs or with potent immunosuppressants such as Azathioprine and Cyclosporine is not recommended.

Dosage in Rheumatoid Arthritis

Tofacitinib/Tofacitinib XR may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). The recommended dose of Tofacitinib is 5 mg twice daily and the recommended dose of Tofacitinib XR is 11 mg once daily.

Switching from Tofacitinib Tablet to Tofacitinib XR Tablets

Patients treated with Tofacitinib 5 mg twice daily may be switched to Tofacitinib XR 11 mg once daily the day following the last dose of Tofacitinib 5 mg.

Dosage Modifications due to Serious Infections and Cytopenias

• It is recommended that Tofacitinib / Tofacitinib XR not be initiated in patients with an absolute lymphocyte count less than 500 cells/mm3, an absolute neutrophil count (ANC) less than 1000 cells/mm3or who have hemoglobin levels less than 9 g/dL.

• Dose interruption is recommended for management of lymphopenia, neutropenia and anemia.

• Avoid use of Tofacitinib / Tofacitinib XR if a patient develops a serious infection until the infection is controlled.

Dosage Modifications due to Drug Interactions In patients receiving:

• Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole), or

• One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., Fluconazole), the recommended dose is Tofacitinib 5 mg once daily.

• Coadministration of potent inducers of CYP3A4 (e.g., Rifampin) with Tofacitinib / Tofacitinib XR may result in loss of or reduced clinical response to Tofacitinib / Tofacitinib XR.

• Coadministration of potent inducers of CYP3A4 with Tofacitinib / Tofacitinib XR is not recommended.

Dosage Modifications in Patients with Renal or Hepatic Impairment In patients with:

• Moderate or severe renal insufficiency, or

• Moderate hepatic impairment, the recommended dose is Tofacitinib 5 mg once daily.

• Use of Tofacitinib / Tofacitinib XR in patients with severe hepatic impairment is not recommended.

USE IN SPECIFIC POPULATIONS

All information provided in this section is applicable to Tofacitinib / Tofacitinib XR as they contain the same active ingredient (Tofacitinib).

Pregnancy Category C.

CONTRAINDICATIONS

None

WARNINGS AND PRECAUTIONS

Avoid use of Tofacitinib/Tofacitinib XR in patients with an active, serious infection, including localized infections. The risks and benefits of treatment should be considered prior to initiating Tofacitinib / Tofacitinib XR in patients:

• with chronic or recurrent infection

• who have been exposed to tuberculosis

• with a history of a serious or an opportunistic infection

• who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or

• with underlying conditions that may predispose them to infection.

SIDE EFFECTS

• upper respiratory tract infections (common cold, sinus infections)

• headache

• diarrhea

• nasal congestion, sore throat, and runny nose (nasopharyngitis)

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

DRUG INTERACTIONS

• Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole): Recommended dose is Tofacitinib 5 mg once daily.

• One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., Fluconazole): Recommended dose is Tofacitinib 5 mg once daily.

• Potent CYP inducers (e.g., Rifampin): May result in loss of or reduced clinical response.

PHARMACEUTICAL INFORMATION

Storage Conditions

Store Tofacitinib / Tofacitinib XR at 20°C to 25°C (68°F to 77°F) dry place, away from light. keep out of reach of children.

Presentation and packaging:

Tofacinix 5 Tablet: Each commercial box contains (3×10’s) 30 tablets in Alu-Alu blister pack.

Tofacinix 11 mg Tablet: Each commercial box contains (3×10’s) 30 tablets in Alu-Alu blister pack.

Buy Tofacinix 5 Mg Online

Are you interested to buy Tofacinix 5 mg online? or you need 11 mg version? Don’t worry. 100 Meds can help you to find reliable and verified medicine at affordable cost. Please contact our support team by using email, whatsapp or wechat. Even you can contact our facebook page.

Reviews

There are no reviews yet.

Be the first to review “Buy Tofacinix 5 mg (Tofacitinib)”

Open chat
1
Need Help?